Patents by Inventor Michelle Rudek

Michelle Rudek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Quantitative determination of nucleoside analogue drugs in genomic DNA or RNA
    Patent number: 11035850
    Abstract: This application provides methods to quantitate drug incorporation into DNA and of simultaneously measuring DNA methylation levels. Drugs include nucleoside analog DNA methyltransferase inhibitors.
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: June 15, 2021
    Assignee: The Johns Hopkins University
    Inventors: Michelle A. Rudek-Renaut, Srinivasan Yegnasubramanian, Nicole Anders
  • QUANTITATIVE DETERMINATION OF NUCLEOSIDE ANALOGUE DRUGS IN GENOMIC DNA OR RNA
    Publication number: 20200041488
    Abstract: This application provides methods to quantitate drug incorporation into DNA and of simultaneously measuring DNA methylation levels. Drugs include nucleoside analog DNA methyltransferase inhibitors.
    Type: Application
    Filed: April 10, 2017
    Publication date: February 6, 2020
    Inventors: Michelle A. Rudek-Renaut, Srinivasan Yegnasubramanian, Nicole Anders
  • Treatment of leukemia with artemisinin derivatives and combinations with other antineoplastic agents
    Patent number: 9918972
    Abstract: Methods of treating cancer, such as leukemia, via administration of therapeutically effective amounts of artemisinins and second agents are detailed herein. The artemisinins include artesunate, dihydroartemisinin, artemether, arteether, artelinate, and ART-838. The second agents include BCL-2 inhibitors such as ABT-199, ABT-263, and ABT-737; kinase inhibitors such as lestaurtinib, midostaurin, and sorafenib; and anti-neoplastic agents such as cytarabine, doxorubicin, etoposide, cyclophosphamide, triplotide, vinorelbine, cisplatin, and rituximab.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: March 20, 2018
    Assignees: THE UNIVERSITY OF MARYLAND, BALTIMORE, THE JOHNS HOPKINS UNIVERSITY
    Inventors: Curt Civin, Xiaochun Chen, Jennifer Fox, Gary Posner, Michelle Rudek
  • TREATMENT OF LEUKEMIA WITH ARTEMISININ DERIVATIVES AND COMBINATIONS WITH OTHER ANTINEOPLASTIC AGENTS
    Publication number: 20160175331
    Abstract: Methods of treating cancer, such as leukemia, via administration of therapeutically effective amounts of artemisinins and second agents are detailed herein. The artemisinins include artesunate, dihydroartemisinin, artemether, arteether, artelinate, and ART-838. The second agents include BCL-2 inhibitors such as ABT-199, ABT-263, and ABT-737; kinase inhibitors such as lestaurtinib, midostaurin, and sorafenib; and anti-neoplastic agents such as cytarabine, doxorubicin, etoposide, cyclophosphamide, triplotide, vinorelbine, cisplatin, and rituximab.
    Type: Application
    Filed: December 23, 2015
    Publication date: June 23, 2016
    Applicant: UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Curt CIVIN, Xiaochun Chen, Jennifer Fox, Gary Posner, Michelle Rudek